Company Overview and News
Franco-Nevada Corporation (FNV - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $61.49 to $65.29 in the past one-month time frame. The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road.
AULGF AU AGG FNV
2018-10-11 zacks - 1
Cabot Oil & Gas Corporation (COG - Free Report) is an independent oil and gas company. The Zacks Consensus Estimate for its current year earnings has been revised 0.9% downward over the last 30 days.
CBSH CBSHP PPG LBRT COG CC FNV CBCB SGH
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
WOPEF LBGO BLT PVG IVN SMNPF TREVF BTG OR FQVLF USAPF CCJ FQM LGDTF DNN OKSWF BHPBF URG DML USAS WPL WOPEY IVPAF PVG BHP BBL BHP OSKGF BHPLF PGLC FNV
2018-09-25 sec.gov - 1
Monday’s announced merger between Barrick Gold Corp. (NYSE: ABX) and Randgold Resources Ltd. (NASDAQ: GOLD) emphasized the quality of the merged company’s reserves, the further reduction in costs and shareholder returns. With gold prices stuck in a relatively narrow range around $1,200, and restive investors who were unhappy with losses, gold miners shifted their strategies to emphasize return on investment rather the expansion regime of eight to 10 years ago.
HMY ABX GFI.WI NEM YRI RGORF AU FCX K GOLD RRS GOLD AULGF KGC AUY AEM AGG GFI GFIOF GG IAG HGMCF FNV ABX
2018-09-22 seekingalpha - 7
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TCBK CAT MET HTH LBCC FIXX CRM BUSE STXB CHFC FIBH FBLV AVGO HBMD CAG SSB ABX MO SBT UMRX PRU MTZ NBHC HOMB EVRI 2914 FFIN BILI OPBK TAP ABRW OZK ACB BREW UNUM OLBK MTN JNJ GHG ALDX BWA VZ FNV EQBK LMT FB JAPAF RAD FNLC AXP 4162 ITYBF PRU CBTX JAPAY PPBI SFNC PNFP TBK CCL KO NCOM NBHOZ CARO TSC BOFIL KBH LION SPPI SMBK PACW DY LTEA BB WSBC TTEC VBTX ABCB DTEA HBNC GNPX FBPRM FBPRL FBPRO XLC FBPRN SNDX CSFL FBPRP MBIN HTWC AZN KMX ACBFF GBCI BATS SIVB KEY BOKF ASNA ABTX HTLF NKE HON TWTR AMAT CELH ROX JBL FBP IMBBY BY CHCO KDP INCY CRON FSB CCL STZ NBEV WTFCW WTFC FBMS WTFCM INTU NBHDZ GOOGL EGBN LTXB STL FBNC BA BB ONB PRGS FBK PFE IMBBF PFBC PH NEM LOXO MNST GOOG PIR RBB TLRY HWC PB BFST NCBS MKC WEED ACN FBSI BBBY DIS BMY OBNK OGE MBNC RNST ABX BOFI CMCSA SNV UBSH WTFPP CGC CADE AZN T IBOC IQ ONE MRK GNTY
2018-09-20 seekingalpha - 2
Free from capital expenditures on finding and developing oil and gas reserves and unburdened by operating costs, the oil royalty firms typically boast an extremely high operating margin.
TGA TGL DMLP VNOM OXY GPRK TPL MGY FNV FANG
After a downward summer for the price of gold and gold mining stocks in general, investors may consider adding Goldcorp (NYSE:GG) stock to their portfolio for the rest of the year. There are several long strategies in GG stock that could lead to impressive profits. If gold recovers, a similar bounce in miners like GG is likely to reward investors well.
ABX NEM GG FNV ABX
There are also important considerations about the various instruments available to investors to gain exposure to gold.
NCMGF NCM ABX NEM TIPS GDX 2840 HCS GLD HSB BRK.A 0005 NCMGY HSEA HSEB GG HSBC FNV ABX HBCYF
Going into Friday's close, more than 20% of the Gold Miners Index had made new lows despite the index itself holding above the $18.15 low put in on August 16th.
TAHO WPM NCMGF FNV.WT.A NGD NCM FNV OKSWF NGDAF NGD RGLD THO NCMGY GOOGL OR OSKGF FNV RGL
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to FNV / Franco-Nevada Corp. on message board site Silicon Investor.
as of ET